IDEAYA Biosciences, Inc. (IDYA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Company Overview - IDEAYA was founded 10 years ago and has established strategic guideposts including first-in-class targets, predictive biomarkers, rational combinations, and early-stage disease focus areas [3] Clinical Pipeline - The company has four clinical pipeline focus areas, with darovasertib being a key program currently in a registrational study, with top-line results expected this quarter for potential accelerated approval filing in the United States [4] - Darovasertib is considered a unique molecule with the potential to define its indication in uveal melanoma across neoadjuvant, adjuvant, and metastatic settings [4] Research Focus - IDEAYA is also focusing on antibody-drug conjugates (ADCs) and DNA damage repair as part of its research and development strategy [5]